“Revolutionizing Cancer Treatment: MiNK Therapeutics’ Groundbreaking Approach to Fighting Advanced Gastroesophageal Cancers at ASCO GI Conference”
Exciting News from MiNK Therapeutics, Inc. at ASCO GI Symposium NEW YORK, Jan. 23, 2025 (GLOBE NEWSWIRE) — MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced a presentation at the American Society…